BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Esposito S, Bianchini S. Dalbavancin for the treatment of paediatric infectious diseases. Eur J Clin Microbiol Infect Dis 2016;35:1895-901. [PMID: 27562407 DOI: 10.1007/s10096-016-2756-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Autore G, Bernardi L, Esposito S. Update on Acute Bone and Joint Infections in Paediatrics: A Narrative Review on the Most Recent Evidence-Based Recommendations and Appropriate Antinfective Therapy. Antibiotics (Basel) 2020;9:E486. [PMID: 32781552 DOI: 10.3390/antibiotics9080486] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
2 Wood JB, Cravens LB, Creech CB. Advances in pediatric antimicrobial agents development. Curr Opin Pediatr 2019;31:135-43. [PMID: 30507647 DOI: 10.1097/MOP.0000000000000713] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Jan IA, Durell J, Lakhoo K. Common Bacterial Infections of Surgical Importance. Pediatric Surgery 2020. [DOI: 10.1007/978-3-030-41724-6_15] [Reference Citation Analysis]
4 Sharma R, Francois D, Hammerschlag MR. New Antimicrobial Agents for the Treatment of Staphylococcal Infections in Children. Pediatr Clin North Am 2017;64:1369-87. [PMID: 29173791 DOI: 10.1016/j.pcl.2017.08.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
5 Pfaller MA, Mendes RE, Sader HS, Castanheira M, Flamm RK. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014–2015). Journal of Global Antimicrobial Resistance 2017;11:4-7. [DOI: 10.1016/j.jgar.2017.06.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
6 Dash RP, Babu RJ, Srinivas NR. Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic. Infectious Diseases 2017;49:483-92. [DOI: 10.1080/23744235.2017.1296968] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]